Does fish oil protect renal function in cyclosporin-treated psoriasis patients?

J Intern Med. 1989 Dec;226(6):437-41. doi: 10.1111/j.1365-2796.1989.tb01421.x.

Abstract

In order to study the influence of fish oil on CyA-induced renal dysfunction, 13 patients with psoriasis (CyA group) received cyclosporin A (CyA) alone, and seven patients (CyA/EPA + DHA group) received a combination of cyclosporin A and fish oil (6g eicosapentaenoic acid, C20:5 omega-3, and docosahexaenoic acid, C22:6 omega-3, daily) for 3 months. The glomerular filtration rate fell by 18.0 +/- 9.6% in the CyA group compared with 8.7 +/- 6.8% in the CyA/EPA + DHA group (mean +/- SD, P less than 0.05). The effective renal plasma flow fell by 10.6 +/- 8.9% in the CyA group and did not change in the CyA/EPA + DHA group (P less than 0.05). The calculated total renal vascular resistance increased by 19.8 +/- 14.5% in the CyA group and did not change in the CyA/EPA + DHA group (P less than 0.01). The results of this pilot study suggest that fish oil can reduce CyA-associated renal dysfunction in psoriasis patients.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cyclosporins / adverse effects
  • Cyclosporins / therapeutic use*
  • Fatty Acids, Unsaturated / therapeutic use*
  • Female
  • Fish Oils / therapeutic use*
  • Humans
  • Kidney Diseases / chemically induced
  • Kidney Diseases / prevention & control*
  • Kidney Function Tests
  • Male
  • Pilot Projects
  • Psoriasis / drug therapy*

Substances

  • Cyclosporins
  • Fatty Acids, Unsaturated
  • Fish Oils
  • SuperEPA